Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer, Axitinib, AG-013736
Brief summary
The purpose of this study is to evaluate the potential role of Axitinib (AG-013736) in the treatment of unresectable/metastatic hepatocellular carcinoma (HCC)
Detailed description
This is a phase II study of an investigational drug, Axitinib following prior antiangiogenic therapy in patients with advanced hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is a primary cancer of the liver. Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels. A tyrosine kinase is an enzyme that can inhibit angiogenesis. In this study, patients with advanced HCC who have failed prior antiangiogenic therapy, will receive Axitinib in cycles of 4 weeks. Axitinib is an oral, potent and selective inhibitor of angiogenesis. This study will evaluate the response rate of HCC following treatment with Axitinib as well as safety, feasibility, overall survival of patients, progression-free survival, and quality of life in persons with unresectable HCC. The study also compares response determined by RECIST to response determined by Choi Criteria.
Interventions
5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
Sponsors
Pfizer
University Health Network, Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Unresectable and/or metastatic Hepatocellular Carcinoma * Previous treatment with tyrosine kinase inhibitors or antiangiogenic drugs * Life expectancy of ≥12 weeks * At least one tumor lesion * At least 2 weeks since the end of prior systemic treatment * No evidence of pre-existing uncontrolled hypertension * ECOG 0 or 1 * Adequate organ function * Not appropriate for curative therapy * Child A or B7 cirrhosis * CLIP score ≤ 4
Exclusion criteria
* Received any other systemic therapy for Hepatocellular Carcinoma within 2 weeks prior to treatment * Major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment * Previous or concurrent cancer that is distinct in primary site or histology from Hepatocellular Carcinoma * Severe acute or chronic medical or psychiatric condition * Need for treatment with prohibited drugs * Has received local therapy to all measurable lesions * Stage B8 or higher liver cirrhosis * Ascites refractory to diuretic therapy * Clinically significant ECG abnormality
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | Response rate assessed by CT scan at 16 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | At the completion of trial, 1.5 years | — |
| Response rate comparison | Comparison of outcomes with RECIST criteria to Choi criteria and changes to perfusion on DCE ultrasound will occur at the end of stage 1 (after accrual of 10 patients) and trial completion | — |
| Progression-free survival | At trial completion, 1.5 years | — |
| Feasibility | Assessed at the end of stage 1 (10 patients accrued) and at the end of trial (Stage 2, 29 patients total) | The ability to administer one or more cycles of Axitinib to \>70% of patients at a dose of 5mg po BID |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | At completion of trial, 1.5 years | Efficacy and Toxicity in Asian vs non-Asian patients will be assessed by comparing the adverse effects profile and rate of grade 3 and grade 4 toxicity in these populations |
| Number of Participants with Adverse Events as a Measure of Safety | At completion of trial, 1.5 years | Adverse effects profile and rate of grade 3 and 4 toxicity will be assessed as a measure of safety |
| Quality of life | At completion of trial, 1.5 years | Assessed by FACT-Hep |
Countries
Canada
Outcome results
None listed